Horizon Gets EC OK for Neuromyelitis Optica Spectrum Disorder Therapy

 

• NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death
• UPLIZNA is indicated as monotherapy for treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+), which represents 80% of NMOSD patients
• EC approval was supported by results from N-MOmemtum, the largest pivotal trial ever conducted in NMOSD, which showed 87.6% of AQP4-IgG+ NMOSD patients on UPLIZNA were attack free for 28 weeks, with the vast majority remaining attack free for at least four or more years
• UPLIZNA is the EU’s first and only targeted CD19+ B-cell-depleting monotherapy proven to reduce attacks in adult AQP4-IgG+ NMOSD patients

https://www.biospace.com/article/releases/horizon-therapeutics-plc-receives-european-commission-ec-approval-of-uplizna-inebilizumab-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-/